318 related articles for article (PubMed ID: 25915587)
1. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha promotes malignant pleural effusion.
Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
[TBL] [Abstract][Full Text] [Related]
3. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
5. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
[TBL] [Abstract][Full Text] [Related]
6. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
[TBL] [Abstract][Full Text] [Related]
7. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutical effects of pleural injecting recombinant human endostain to
malignant pleural effusion nude mice model].
Zhou M; Li M; Yang H; Hu C
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):266-71. PubMed ID: 25975296
[TBL] [Abstract][Full Text] [Related]
9. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Arsenic Trioxide in the Treatment of Malignant Pleural Effusion Caused by Pleural Metastasis of Lung Cancer.
Xie SL; Yang MH; Chen K; Huang H; Zhao XW; Zang YS; Li B
Cell Biochem Biophys; 2015 Apr; 71(3):1325-33. PubMed ID: 25413961
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
12. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer.
Su WP; Chen YT; Lai WW; Lin CC; Yan JJ; Su WC
Lung Cancer; 2011 Jan; 71(1):28-33. PubMed ID: 20430468
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
[TBL] [Abstract][Full Text] [Related]
16. Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.
Yang G; Li H; Yao Y; Xu F; Bao Z; Zhou J
Oncol Rep; 2015 Jan; 33(1):478-84. PubMed ID: 25371165
[TBL] [Abstract][Full Text] [Related]
17. The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.
Kovacs M; Alamón C; Maciel C; Varela V; Ibarburu S; Tarragó L; King PH; Si Y; Kwon Y; Hermine O; Barbeito L; Trias E
Acta Neuropathol Commun; 2021 Aug; 9(1):136. PubMed ID: 34389060
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Cerny-Reiterer S; Rabenhorst A; Stefanzl G; Herndlhofer S; Hoermann G; Müllauer L; Baumgartner S; Beham-Schmid C; Sperr WR; Mannhalter C; Sill H; Linkesch W; Arock M; Hartmann K; Valent P
Oncotarget; 2015 Feb; 6(5):3071-84. PubMed ID: 25605011
[TBL] [Abstract][Full Text] [Related]
19. Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.
Lv M; Leng JH; Hao YY; Sun Y; Cha N; Wu GP
Diagn Cytopathol; 2015 Jul; 43(7):527-31. PubMed ID: 25346242
[TBL] [Abstract][Full Text] [Related]
20. C-Kit controls IL-1β-induced effector functions in HMC-cells.
Drube S; Schmitz F; Göpfert C; Weber F; Kamradt T
Eur J Pharmacol; 2012 Jan; 675(1-3):57-62. PubMed ID: 22173128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
